Design and in vivo activity of A3 adenosine receptor agonist prodrugs.

Abstract

Prodrugs (MRS7422, MRS7476) of highly selective A3 adenosine receptor (AR) agonists Cl-IB-MECA and MRS5698, respectively, were synthesized by succinylation of the 2' and 3' hydroxyl groups, and the parent, active drug was shown to be readily liberated upon incubation with liver esterases. The prodrug MRS7476 had greatly increased aqueous solubility compared with parent MRS5698 and was fully efficacious and with a longer duration than MRS7422 in reversing mouse neuropathic pain (chronic constriction injury model, 3 μmol/kg, p.o.), a known A3AR effect. MRS7476 (5 mg/kg, p.o., twice daily) was found to protect against non-alcoholic steatohepatitis (NASH) in the STAM mouse model, indicated by the NAFLD activity score. Hepatocyte ballooning, IL-10 production, and liver histology were significantly normalized in the MRS7476-treated mice, but not liver fibrosis (no change in ACTA2 levels) or inflammation. Hepatic expression of ADORA3 in human NAFLD patients was 1.9-fold lower compared to normal controls. Adora3 expression determined by qPCR in primary mouse liver was associated with the stellate cells, and its mouse full body A3AR knockout worsened liver markers of inflammation and steatosis. Thus, we have introduced a reversible prodrug strategy that enables water solubility and in vivo activity of masked A3AR agonists in models of two disease conditions.

• Authors: R Rama Suresh, Shanu Jain, Zhoumou Chen, Dilip K Tosh, Yanling Ma, Maren C Podszun, Yaron Rotman, Daniela Salvemini, Kenneth A Jacobson
• Journal: Purinergic signalling (Purinergic Signal) Vol. 16 Issue 3 Pg. 367-377 (09 2020) ISSN: 1573-9546 [Electronic] Netherlands
• PMID: 32720036 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)

Chemical References

• Adenosine A3 Receptor Agonists
• MRS5698
• Prodrugs
• Adenosine
• 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide

Topics

• Adenosine (analogs & derivatives, chemistry, therapeutic use)
• Adenosine A3 Receptor Agonists (chemistry, therapeutic use)
• Animals
• Disease Models, Animal
• Drug Design
• Inflammation (prevention & control)
• Mice
• Neuralgia (drug therapy)
• Non-alcoholic Fatty Liver Disease (prevention & control)
• Prodrugs (chemistry, therapeutic use)